FindTrial
Sign In

network meta-analysis of first-line treatment for ALK-positive NSCLC

network meta-analysis of first-line treatment for ALK-positive NSCLC - NMA of 1L ALK inhibitors

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000042744
Enrollment
Unknown
Registered
2020-12-14
Start date
2020-12-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ALK-positive NSCLC

Interventions

None listed

Sponsors

Yokohama City University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: English-written individually randomized controlled trials for ALK-positive NSCLC will be included. A trial should have recruited untreated, chemo-naive, or ALK naive patients.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
OS—

Secondary

MeasureTime frame
PFS, ORR, AE(>g3), TRD—

Countries

Japan

Contacts

Public ContactNobuyuki Horita

Yokohama City University Department of Pulmonology

horitano@yokohama-cu.ac.jp+81457872800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026